Mr. Thomas Smeenk reports

HEMOSTEMIX STARTS ITS ROLL-UP OF CARDIOLOGY PRACTICES, ACQUIRING ITS FIRST TWO

Hemostemix Inc. has signed a binding letter of intent for the acquisition of the first two cardiology practices under the company's clinic roll-up and commercialization strategy. The practices of Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, two of the Dominican Republic's most respected interventional cardiologists, will be acquired by Hemostemix for two million shares each, subject to adjustment and TSX Venture Exchange approval.

This marks the first of many acquisitions, as Hemostemix's long-term strategy to acquire profitable, accretive medical practices within which it can add ACP-01 treatments. Capable of generating a sustainable, predictable commercial stream of patients for treatment with ACP-01, the company's operations strategy will focus on patient treatment flow, while the company's sales team focus on leveraging the practitioner-to-practitioner dialogue to increase the number of practitioners treating with ACP-01 (patient volumes).

Two cardiologists with more than 200 ACP-01 patient treatments

Combined, Dr. Fernandez-de-Castro and Dr. Rosario Figueroa have treated more than 200 patients with ACP-01, making them among the most experienced ACP-01 clinicians globally. Given their record as pioneers in the safe treatment of end-stage no-option CVD patients, Dr. Fernandez de Castro and Dr. Rosario Figueroa have the credibly to attest to the safety, feasibility, clinical relevancy and observed efficacy of ACP-01 to patients, referring physicians, hospital partners and regulators.

Their experience spans multiple indications, including:

• Angina;
• Ischemic and dilated cardiomyopathy;
• Congestive heart failure;
• Peripheral arterial disease;
• Chronic limb-threatening ischemia;
• Vascular dementia.

Their clinical expertise, long-standing patient bases and reputations within the Dominican Republic's medical community position them as ideal anchor practices for Hemostemix's first international clinical and commercial footprint.

Under the terms of the LOI, Dr. Roberto Fernandez-de-Castro and Dr. Rosario Figueroa:

• Will each contribute his medical expertise and experience in cardiovascular disease treatments of angina, ischemic and dilated cardiomyopathy, congestive heart failure, peripheral arterial disease, chronic limb threatening ischemia, and vascular dementia;
• Will actively participate in the clinical implementation of ACP-01 therapy within the Dominican Republic and the Bahamas;
• Will facilitate the necessary regulatory approvals and interactions with Dominican Republic health authorities;
• Will each sell his existing medical practice to Hemostemix in exchange for the issuance of two million common shares.

The integration of these practices will commence Hemostemix clinical infrastructure, accelerate ACP-01 commercialization and provide the foundation for future clinical trial expansion. It provides a turnkey profit structure that enables hands-on care and follow-up with ACP-01 recipients, which is a significant contributor to improved health outcomes.

This model is designed to be replicated across additional markets, including Florida, Puerto Rico and Canada, under various pathways.

"This acquisition is a transformational milestone for Hemostemix," stated Thomas Smeenk, chief executive officer. "Dr. Fernandez-de-Castro and Dr. Rosario Figueroa are world-class cardiologists who have successfully treated 200 ACP-01 patients. Their first-hand experience, results as published and clinical conviction provide a powerful foundation for accelerating ACP-01 in North America. These acquisitions are the first of many, as they enable us to focus advertising and patients flow in a regulatory compliant manner that is financially rewarding," Mr. Smeenk said.

TSX-V financing extension

The TSX-V has approved an extension to Dec. 1 of the terms of the non-brokered private placement of units at 11 cents as announced on Oct. 8, 2025, and as updated Nov. 4, 2025. The company raised aggregate gross proceeds of $461,230 through the issuance of 4,193,000 units at a price of 11 cents per unit, to date. Each unit consists of one common share in the capital of the company and one common share purchase warrant. Each full warrant entitles the holder to acquire one additional common share at a price of 15 cents per share for a period of two years from the closing date of the offering, subject to the accelerated expiry provision described as follows. If, on any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date, the closing sales price of the common shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX-V is greater than a weighted average price of 18.5 cents per common share, the company may provide notice in writing to the holders of the warrants by issuance of a news release that the expiry date of the warrants will be accelerated to the date that is 30 days following such news release.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed and patented, and is scaling and selling, autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, the University of British Columbia and the University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain, wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.